Strata Skin Sciences (SSKN)
(Delayed Data from NSDQ)
$0.91 USD
-0.06 (-6.69%)
Updated Mar 24, 2023 12:25 PM ET
2-Buy of 5 2
B Value F Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.91 USD
-0.06 (-6.69%)
Updated Mar 24, 2023 12:25 PM ET
2-Buy of 5 2
B Value F Growth B Momentum C VGM
Zacks News
New Strong Buy Stocks for February 14th
by Zacks Equity Research
INSP, ALK, SSKN, NVO and TBPH have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.
Strata Skin Sciences, Inc. (SSKN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 50% and 11.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Tabula Rasa Healthcare (TRHC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of -1,366.67% and 4.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Strata Skin Sciences, Inc. (SSKN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of -25% and 12.27%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Health Catalyst (HCAT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Health Catalyst (HCAT) delivered earnings and revenue surprises of 72.73% and 1.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Strata Skin Sciences, Inc. (SSKN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of -40% and 1.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Health, Inc. (HIMS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of 11.11% and 12.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Axonics Modulation Technologies (AXNX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 27.54% and 7.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Strata Skin Sciences, Inc. (SSKN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 33.33% and 0.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Invitae (NVTA) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Invitae (NVTA) delivered earnings and revenue surprises of -9.46% and 1.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Hims & Hers Health, Inc. (HIMS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) delivered earnings and revenue surprises of -10% and 11.42%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Strata Skin Sciences, Inc. (SSKN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 50.00% and -0.94%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Strata Skin Sciences, Inc. (SSKN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strata Skin Sciences, Inc. (SSKN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 50.00% and 14.36%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Strata Skin Sciences, Inc. (SSKN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strata Skin Sciences, Inc. (SSKN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strata Skin Sciences, Inc. (SSKN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) delivered earnings and revenue surprises of 50.00% and 0.33%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Strata Skin Sciences, Inc. (SSKN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strata Skin Sciences, Inc. (SSKN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Strata Skin Sciences, Inc. (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Strata Skin (SSKN) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Strata Skin (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Strata Skin (SSKN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Strata Skin (SSKN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top 10 Stocks Under $20
by Ryan McQueeney
Today we've highlighted ten stocks that are currently trading for under $20 per share. All of these stocks currently have at least a Zacks Rank #2 (Buy), and a variety of other factors make these companies stand out as having strong upside potential.
Has Strata Skin Sciences (SSKN) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (SSKN) Outperforming Other Medical Stocks This Year?
Is Strata Skin Sciences (SSKN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (SSKN) Outperforming Other Medical Stocks This Year?